Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

757.50 +8.79 (+1.17%)

Streaming Delayed Price Updated: 9:55 AM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

58 59 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

February 12, 2024

Via Benzinga

These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys? ↗

February 09, 2024

There's room for multiple winners in the fast-growing weight-loss market.

Via The Motley Fool

The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition ↗

February 06, 2024

Some of the best stocks to buy in February according to MarketMaster AI suggest that a major economic recovery is underway.

Via InvestorPlace

Topics Artificial Intelligence

Regeneron Announces Investor Conference Presentations

February 06, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

$100 Invested In This Stock 20 Years Ago Would Be Worth $6,400 Today ↗

February 06, 2024

Via Benzinga

Earnings Outlook For Regeneron Pharmaceuticals ↗

February 01, 2024

Via Benzinga

Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views ↗

January 29, 2024

Via Benzinga

4D Molecular Therapeutics' 4D-150 Phase 2 Data Met Investor Expectations, Analyst Boosts Forecast ↗

February 06, 2024

4D Molecular Therapeutics' 4D-150 Phase 2 results for wet AMD treatment. BMO Capital optimistic, target price raised to $70.

Via Benzinga

Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗

February 06, 2024

Via Benzinga

Stock-Split Watch: Could These 2 Market-Beaters Be Next? ↗

February 06, 2024

Investors might continue bidding up shares of these companies regardless.

Via The Motley Fool

Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today? ↗

February 05, 2024

4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity.

Via Benzinga

Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗

February 02, 2024

The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.

Via Benzinga

Topics Economy

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? ↗

February 02, 2024

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.

Via Benzinga

The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High ↗

February 02, 2024

Shares usually rally on Eylea news, but Regeneron stock is on the rise following fourth-quarter beats from two other products.

Via Investor's Business Daily

Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year ↗

February 02, 2024

Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.

Via Benzinga

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

February 02, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

February 02, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For February 2, 2024 ↗

February 02, 2024

Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion.

Via Benzinga

3 Top Pharma Stocks to Buy Now: February 2024 ↗

February 01, 2024

Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.

Via InvestorPlace

Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't. ↗

February 01, 2024

The company missed total sales and earnings expectations.

Via Investor's Business Daily

Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

January 30, 2024

Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AI, Biotech, Energy Sectors Expect M&A Revival For 2024 ↗

January 29, 2024

The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.

Via Benzinga

Topics Artificial Intelligence

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

3 Magnificent Stocks to Buy and Hold Forever ↗

January 27, 2024

Many investors will want to consider owning these stocks for a long time.

Via The Motley Fool

Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation ↗

January 26, 2024

FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.

Via Benzinga

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

January 25, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts ↗

January 24, 2024

UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.

Via Benzinga

Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

January 24, 2024

Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024 ↗

January 23, 2024

Blue-chip healthcare stocks combine stability, profitability, and long-term growth prospects into a single investable package.

Via InvestorPlace

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

58 59 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today